Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Jul 2;8(7):e68273.
doi: 10.1371/journal.pone.0068273. Print 2013.

Axial low back pain: one painful area--many perceptions and mechanisms

Affiliations
Multicenter Study

Axial low back pain: one painful area--many perceptions and mechanisms

Matti Förster et al. PLoS One. .

Abstract

Axial low back pain can be considered as a syndrome with both nociceptive and neuropathic pain components (mixed-pain). Especially neuropathic pain comprises a therapeutic challenge in practical experience and may explain why pharmacotherapy in back pain is often disappointing for both the patient and the therapist. This survey uses epidemiological and clinical data on the symptomatology of 1083 patients with axial low back pain from a cross sectional survey (painDETECT). Objectives were (1) to estimate whether neuropathic pain contributes to axial low back pain and if so to what extent. (2) To detect subgroups of patients with typical sensory symptom profiles and to analyse their demographic data and co-morbidities. (3) To compare patients with and without prior intervertebral disc surgery (IVD). Neuropathic pain components could be detected in 12% of the entire cohort. Cluster analyses of these patients revealed five distinct subgroups of patients showing a characteristic sensory profile, i.e. a typical constellation and combination of symptoms. All subgroups occurred in relevant numbers and some showed distinct neuropathic characteristics while others showed nociceptive features. Post-IVD-surgery patients showed a tendency to score more "neuropathic" than patients without surgery (not statistically significant). Axial low back pain has a high prevalence of co-morbidities with implication on therapeutic aspects. From these data it can be concluded that sensory profiles based on descriptor severity may serve as a better predictor for therapy assessment than pain intensity or sole diagnosis alone. Standardized phenotyping of pain symptoms with easy tools may help to develop an individualized therapy leading to a higher success rate in pharmacotherapy of axial low back pain.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have the following interests. This research was supported by a grant from Pfizer Germany without restriction on publication. Data was collected within the PainDetect project, which was funded by Pfizer. Ulrich Gockel is employed by Casquar GmbH and is a part-time worker for Grünenthal GmbH International medical affairs department. Mathias Brosz is employed by StatConsult GmbH. StatConsult maintains painDETECT, and supports research technically as well as statistically. MB has analyzed the complete data which was held at the central data-processing facility StatConsult GmbH, Magdeburg (Germany). MF is a member of the IMI Europain consortium. He has received speaking fees from Pfizer, Denmark and Grünenthal. FM is a member of the IMI Europain consortium. She has received research support, consulting, or speaking fees from Grünenthal and Pfizer. RF has received research support, consulting or speaking fees from Astellas, Epionics, Forest research, HRA, Grünenthal, Lilly, Boehringer, Pfizer, UCB, Schwarz Pharma. TRT has received consulting and speaking fees from Pfizer, Grünenthal, Lilly, Epionics, UCB, Mundipharma, Pharmaleads. RB receives grants/research support from the following organizations: Pfizer, Genzyme, Grünenthal. RB is a member of the IMI Europain consortium IMI “Europain” collaboration and industry members of this are: Astra Zeneca, Pfizer, Esteve, UCB-Pharma, Sanofi Aventis, Grünenthal, Eli Lilly and Boehringer Ingelheim. He has received speaking fees from Pfizer, Genzyme, Grünenthal, Mundipharma, Sanofi Pasteur, Medtronic, Eisai, UCB BioSciences, Lilly, Boehringer Ingelheim, Astellas, Desitin and Teva Pharma. He has been a consultant to Pfizer, Genzyme, Grünenthal, Mundipharma, Allergan, Sanofi Pasteur, Medtronic, Eisai, UCB BioSciences, Lilly, Boehringer Ingelheim, Astellas, Novartis, Bristol-Myers Squibb, Biogenidec and AstraZeneca. There are no further patents, products in development, or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Figures

Figure 1
Figure 1. Differences in PD-Q scores in the subgroups.
The different scores calculated from the PD-Q are shown, revealing the proportion of positive, i.e. neuropathic and negative, i.e. non-neuropathic as well as unclear results. Patients from clusters 3 and 4 showed the tendency to score more neuropathic than those from clusters 1, 2 and 5.
Figure 2
Figure 2. Subgroups of patients based on their sensory symptoms.
To identify relevant subgroups of patients who are characterized by a characteristic symptom constellation a hierarchical cluster analysis was performed. The clusters are represented by the patterns of questionnaire scores (A: adjusted individual mean; B: non-adjusted values), thus showing the typical pathological structure of the respecting group. By using this approach five clusters with distinct symptom profiles could be detected in the cohort. Sensory profiles show remarkable differences in the expression of the symptoms. Subgroup 5 does not show any outstanding symptoms and low prevalence of symptoms in general.
Figure 3
Figure 3. Differences in PD-Q scores after IVD-surgery.
The pie-chart depicts the proportion of patients with and without IVD-surgery scoring “positive”, “unclear” or “negative” in the PD-Q. There are no significant differences between the respective groups (χ2-Test, p = 0.2215).

Similar articles

Cited by

References

    1. Freynhagen R, Baron R, Tolle T, Stemmler E, Gockel U, et al. (2006) Screening of neuropathic pain components in patients with chronic back pain associated with nerve root compression: a prospective observational pilot study (MIPORT). Curr Med Res Opin 22: 529–537. - PubMed
    1. Schmidt CO, Schweikert B, Wenig CM, Schmidt U, Gockel U, et al. (2009) Modelling the prevalence and cost of back pain with neuropathic components in the general population. Eur J Pain 13: 1030–1035. - PubMed
    1. Baron R, Freynhagen R, Tolle TR, Cloutier C, Leon T, et al. (2010) The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 150: 420–427. - PubMed
    1. Khoromi S, Cui L, Nackers L, Max MB (2007) Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 130: 66–75. - PMC - PubMed
    1. Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, et al. (2005) Topiramate in chronic lumbar radicular pain. J Pain 6: 829–836. - PubMed

Publication types

MeSH terms

Grants and funding

This research was supported by a grant from Pfizer Germany without restriction on publication. Data was collected within the PainDetect project, which was funded by Pfizer. The funder had no role in study design, analysis, decision to publish, or preparation of the manuscript.

LinkOut - more resources